$1.42
+0.04(2.90%)
Mkt Cap $11M
$1.06
$12.30
52-Week Range
At A Glance
1
BioVie Inc., a clinical stage biotechnology company, engages in the discovery, development, and commercialization of drugs therapies in the United States.
2
No significant events in the past 90 days.
$11M
Market Cap
—
Revenue
-$17M
Net Income
Employees14
Fundamentals
How The Business Makes Money
BioVie Inc., a clinical stage biotechnology company, engages in the discovery, development, and commercialization of drugs therapies in the United States. Its products in pipeline include BIV201, which completed Phase IIa clinical trial for the treatment of ascites due to chronic liver cirrhosis; and NE3107, which is in Phase III clinical trial for the treatment of patients with mild to moderate Alzheimer's disease and Phase I clinical trial for the treatment of Parkinson's disease. The company is also developing NE3107, which is in pre-clinical stage for the treatment of multiple myeloma and prostate cancer. The company was formerly known as NanoAntibiotics, Inc. and changed its name to BioVie Inc. in July 2016. BioVie Inc. was incorporated in 2013 and is based in Carson City, Nevada.
Industry Biotechnology
Activity
What Changed Recently
No significant events in the past 90 days.
Analyst View
Company Profile
CIK0001580149
ISINUS09074F5044
CUSIP09074F504
Phone775 888 3162
Address680 West Nye Lane, Carson City, NV, 89703, US
SEC EDGAR